GETUG-AFU 31 挽救性前列腺立体定向再放疗试验的靶区勾画与剂量学一致性质量保证
该研究报道了 GETUG-AFU 31 试验中 18 家中心参与的治疗前质量保证流程,评估靶区及危及器官勾画一致性和计划剂量学质量。结果显示 5 家中心(28%)需重新提交,GTV、CTV 和尿道勾画变异性高,而膀胱、直肠和前列腺一致性较好;修订后所有计划均满足剂量约束。
要点
- 18 家中心中 5 家(28%)因勾画或计划问题需重新提交。
- GTV、CTV 和尿道勾画一致性低,膀胱、直肠和前列腺一致性较高。
- 修订后所有计划均满足协议剂量约束。
核心结论
- 在挽救性前列腺 SBRT 中,靶区体积和尿道勾画的重复性至关重要,正式指南有待制定。
研究设计与样本
- GETUG-AFU 31 为多中心 I/II 期试验,评估 6×6 Gy SBRT,治疗前进行勾画和剂量学演练。
- 18 家中心使用复发灶的 CT、PET 和多参数前列腺 MRI 数据集勾画靶区及危及器官,并与专家参考比较。
主要发现
- 18 家中心中 5 家(28%)需要重新提交。
- GTV 中位 DSC 为 0.63(IQR 0.45-0.70),HD avg >1.8 mm;CTV 中位 DSC 为 0.79(IQR 0.71-0.82),HD avg >1.8 mm;尿道中位 DSC 为 0.10(IQR 0.05-0.26),HD avg >3.6 mm。
- 膀胱 DSC 为 0.93,直肠为 0.85,前列腺为 0.85。
关键数值与推荐
- 修订后所有计划满足约束:CTV Dmedian > 38.1 ± 1.4 Gy。
- 直肠壁 V27Gy 平均 0.33 ± 0.23 cc(≤1 cc),膀胱壁 V27Gy 平均 0.88 ± 0.32 cc(≤2 cc)。
- 尿道 D0.035cc 为 37.0 ± 1.0 Gy(≤39 Gy)。
临床怎么用
- 多中心开展前列腺再放疗 SBRT 前应执行勾画和剂量学演练,重点规范 GTV、CTV 和尿道勾画。
局限性
- 本文仅报告治疗前质量保证流程结果,未报告临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Salvage stereotactic body radiotherapy (SBRT) represents a promising approach for managing intraprostatic recurrence following radiotherapy. The multicenter phase I/II GETUG-AFU 31 trial evaluated 6 × 6 Gy SBRT, with delineation and dosimetric dummy runs performed to ensure consistent target and organ-at-risk (OAR) delineation and treatment plan quality across centers. We report the outcomes of this pre-accrual quality reassurance process. MATERIALS AND METHODS: Eighteen centers received CT, PET, and multiparametric prostate MRI (mpMRI) datasets of recurrent lesions and contoured the gross target volume (GTV), clinical target volume (CTV), prostate, bladder/rectum (whole and wall), penile bulb, and urethra + 3 mm. The Dice similarity coefficient (DSC) and average Hausdorff distance (HD avg) were calculated against an expert reference. Each center subsequently generated a 6 × 6-Gy plan on another anonymized dataset. Dose-volume indices were compared with the protocol limits. Major deviations were subsequently revised. RESULTS: Of the 18 centers, 5 (28 %) required resubmission. Variability was high for the GTV (median DSC: 0.63 [interquartile range {IQR}: 0.45-0.70; HD avg: >1.8 mm), CTV: (0.79 [0.71-0.82]; HDavg: >1.8 mm), and urethra: (0.10 [0.05-0.26]; HD avg: >3.6 mm). Larger structures showed higher agreement: bladder, 0.93; rectum, 0.85; prostate, 0.85. All revised plans satisfied constraints: CTV Dmedian > 38.1 ± 1.4 Gy; rectal-wall V27Gy averaged 0.33 ± 0.23 cc (≤1 cc), bladder-wall V27Gy averaged 0.88 ± 0.32 cc (≤2 cc); urethral D0.035cc was 37.0 ± 1.0 Gy (≤39 Gy). CONCLUSIONS: The reproducibility of the target volume and urethral delineation is essential in the context of salvage radiotherapy, for which formal guidelines are anticipated.
引用
- Tonneau M, Bartau C, Lacornerie T, et al. Quality assurance of contouring and dosimetric consistency in the GETUG-AFU 31 salvage prostate stereotactic reirradiation trial. Radiother Oncol. 2025. PMID: 41167280. doi:10.1016/j.radonc.2025.111240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。